POU2F2

Summary

POU2F2 (POU class 2 homeobox 2, HGNC:9213) is a protein-coding gene on chromosome 19q13.2, encoding POU domain, class 2, transcription factor 2 (P09086). Transcription factor that specifically binds to the octamer motif (5’-ATTTGCAT-3’).

The protein encoded by this gene is a homeobox-containing transcription factor of the POU domain family. The encoded protein binds the octamer sequence 5’-ATTTGCAT-3’, a common transcription factor binding site in immunoglobulin gene promoters. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5452 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 67 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): activating (oncogene-like) across 3 cancer types
• Transcription factor: yes — 57 downstream targets (CollecTRI)
• MANE Select transcript: NM_001394376

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9213
Approved symbol	POU2F2
Name	POU class 2 homeobox 2
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	OCT2
Ensembl gene	ENSG00000028277
Ensembl biotype	protein_coding
OMIM	164176
Entrez	5452

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 18 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000342301, ENST00000389341, ENST00000524801, ENST00000526816, ENST00000526831, ENST00000528894, ENST00000529067, ENST00000529952, ENST00000530982, ENST00000531773, ENST00000532176, ENST00000533548, ENST00000534559, ENST00000558596, ENST00000560398, ENST00000560558, ENST00000560804, ENST00000598842, ENST00000625670, ENST00000636631, ENST00000692977, ENST00000932778

RefSeq mRNA: 10 — MANE Select: NM_001394376 NM_001207025, NM_001207026, NM_001247994, NM_001393934, NM_001393935, NM_001393936, NM_001394376, NM_001394377, NM_001394378, NM_002698

CCDS: CCDS33035, CCDS56094, CCDS56095, CCDS58665, CCDS92629, CCDS92631

Canonical transcript exons

ENST00000692977 — 15 exons

Exon	Start	End
ENSE00002190414	42117250	42117432
ENSE00002488084	42091867	42091940
ENSE00003519293	42092069	42092270
ENSE00003539367	42093829	42093895
ENSE00003586433	42095545	42095693
ENSE00003683153	42095286	42095462
ENSE00003696826	42096082	42096243
ENSE00003700591	42122126	42122182
ENSE00003701252	42122344	42122378
ENSE00003701287	42122511	42122576
ENSE00003702030	42099527	42099618
ENSE00003702405	42099716	42099821
ENSE00003787082	42095788	42095929
ENSE00003933084	42086110	42091591
ENSE00003936177	42132384	42132446

Expression profiles

Bgee: expression breadth ubiquitous, 236 present calls, max score 97.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5729 / max 118.0688, expressed in 971 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181140	4.8012	856
181142	0.3161	117
181141	0.2704	135
181139	0.1618	66
181138	0.0234	11

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	97.38	gold quality
mononuclear cell	CL:0000842	97.15	gold quality
buccal mucosa cell	CL:0002336	96.95	gold quality
leukocyte	CL:0000738	96.86	gold quality
granulocyte	CL:0000094	94.87	gold quality
endometrium epithelium	UBERON:0004811	93.70	gold quality
lymph node	UBERON:0000029	91.74	gold quality
pancreatic ductal cell	CL:0002079	91.67	silver quality
paraflocculus	UBERON:0005351	90.06	gold quality
blood	UBERON:0000178	89.88	gold quality
vena cava	UBERON:0004087	89.11	silver quality
frontal pole	UBERON:0002795	88.77	gold quality
middle frontal gyrus	UBERON:0002702	88.20	gold quality
triceps brachii	UBERON:0001509	86.73	gold quality
spleen	UBERON:0002106	86.66	gold quality
vermiform appendix	UBERON:0001154	86.11	gold quality
gluteal muscle	UBERON:0002000	85.87	gold quality
caecum	UBERON:0001153	85.73	gold quality
sperm	CL:0000019	85.49	silver quality
male germ cell	CL:0000015	85.01	gold quality
tendon of biceps brachii	UBERON:0008188	85.00	gold quality
cerebellar vermis	UBERON:0004720	84.39	gold quality
tonsil	UBERON:0002372	83.80	gold quality
Brodmann (1909) area 10	UBERON:0013541	83.47	silver quality
nipple	UBERON:0002030	82.92	gold quality
bone marrow cell	CL:0002092	82.33	gold quality
superior surface of tongue	UBERON:0007371	82.17	gold quality
cerebellar cortex	UBERON:0002129	81.82	gold quality
cerebellar hemisphere	UBERON:0002245	81.75	gold quality
superficial temporal artery	UBERON:0001614	81.71	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-93593	yes	92.63
E-CURD-122	yes	83.98
E-ANND-3	yes	21.69
E-GEOD-135922	yes	10.40
E-HCAD-10	yes	4.36
E-GEOD-36552	no	48.05

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

57 targets.

Target	Regulation
ATP11C
BCL2	Activation
BTK
CCR5	Activation
CD36
CR2
CRISP3
CSF3	Activation
CSN2	Activation
EMC10
ETS1	Unknown
GNAS
GNRH1
H2AC18
H2BC11
HBB	Unknown
HLA-DOB	Unknown
HLA-DRA	Unknown
HMGA1	Activation
ID2	Unknown
IFNG
IGH
IGHM
IL2	Activation
IL3	Activation
IL4	Activation
IL5	Unknown
IL5RA
ITGAX
IVL	Repression

JASPAR motifs

Motif	Name	Family
MA0507.1	POU2F2	POU domain factors
MA0507.2	POU2F2	POU domain factors
MA0507.3	POU2F2	POU domain factors

JASPAR matrix evidence (PMIDs): PMID:11937630

Upstream regulators (CollecTRI, top): NFKB1, POU2F1, RELA, TCF3

miRNA regulators (miRDB)

204 targeting POU2F2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029

Literature-anchored findings (GeneRIF, showing 29)

• The function of human Oct-2 in immunoglobulin(Ig)-secreting cells requires plasmacytoma-specific coativator OCA-B working synergistically to sustain the gene expression profile of the Ig-secreting cell. (PMID:14662861)
• DNase I-hypersensitive site 4 (hs4) enhancer activity in mature Burkitt’s lymphoma B cells is regulated by synergistic involvement of both Oct-2 and NF-kappa B family members; Oct-2 is required for hs4 enhancer activity. (PMID:14707079)
• Alteration of the OCT2 locus does not correlate with its suppressed expression in Hodgkin lymphoma. (PMID:15796964)
• physical binding to the family of repeats in Epstein-Barr virus oriP by the cellular transcription factors Oct-1 and Oct-2 was demonstrated by using an electrophoretic mobility-shift assay (PMID:15831936)
• Oct-2, therefore, acts as a cell survival factor in t(14;18) lymphoma cells by directly activating the antiapoptotic gene bcl-2. (PMID:16186795)
• The transcription factors Oct-1 and -2 inhibit and enhance, respectively, the expression of exon 1-containing transcripts and CCR5 surface levels. (PMID:17442950)
• Oct-2 and its cofactor Bob-1 have an important function in mediating the IgH enhancer-bcl-2 promoter region interactions (PMID:18695675)
• Oct-2, was studied in detail and found to be a bifunctional regulator: It can either repress or induce neuronal differentiation, depending on the particular isoform (PMID:19270158)
• Data suggest that OCT2 and/or OCT3 might be involved in the initial component of histamine uptake, whereas the later component of histamine uptake is likely to be mediated by another, as yet undefined uptake system(s). (PMID:19271143)
• Renal OCT2 expression is no important in the renal excretion of metformin (PMID:19536068)
• OCT-2 may act as a cell survival factor in acute myeloid leukemia by mediating expression of downstream targets, such as BCL-2. (PMID:20141429)
• Gefitinib may exert an inhibitory effect on the intracellular accumulation of drugs transported by hOCT1 and hOCT2. (PMID:20363215)
• Twenty-two cases of nodular lymphocyte predominant Hodgkin lymphoma were studied for the immunohistochemical expression of Pax-5, Oct-2, BOB.1, Bcl-6 protein and MUM1/IRF-4. (PMID:21424034)
• Half of the cases displayed Oct-2 expression (15/30 cases) of systemic anaplastic large-cell lymphoma measured by tissue microarray immunohistochemistry. (PMID:22158496)
• B-cell specific transcription factor, Oct-2, inhibits the function of the viral immediate-early protein, BZLF1, and prevents lytic viral reactivation. Oct-2 potentiates establishment of EBV latency in B cells. (PMID:22346751)
• a differential control exerted by both Oct-1 and Oct-2 in the transcriptional regulation of the HMGA1 gene (PMID:24367622)
• Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. (PMID:24435047)
• POU2F2 regulated ROBO1 transcription, thus functionally contributing to Gastric cancer metastasis. (PMID:26019213)
• findings show that cellular factors OCT2 and HCF1 bind OriP in association with Epstein-Barr virus nuclear antigen 1 to maintain elevated histone H3K4me3 and transcriptional enhancer function (PMID:27009953)
• Identification of novel prostate cancer drivers, ERF, CREB3L1, and POU2F2, using RegNetDriver, a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. (PMID:28750683)
• OBF1 and Oct factors control the germinal center transcriptional program. (PMID:33512466)
• POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1. (PMID:33832481)
• POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway. (PMID:33931589)
• Long Non-Coding RNA ARAP1-AS1 Facilitates the Progression of Cervical Cancer by Regulating miR-149-3p and POU2F2. (PMID:33965958)
• CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer. (PMID:35526483)
• OCT2 expression in histiocytoses. (PMID:36754897)
• The MYC-regulated lncRNA LNROP (ENSG00000254887) enables MYC-driven cell proliferation by controlling the expression of OCT2. (PMID:36849510)
• Transcriptional Coactivator BOB1 (OBF1, OCA-B) Modulates the Specificity of DNA Recognition by the POU-Domain Factors OCT1 and OCT2 in a Monomeric Configuration. (PMID:38254723)
• POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis. (PMID:38318853)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	pou2f2b	ENSDARG00000019658
mus_musculus	Pou2f2	ENSMUSG00000008496
rattus_norvegicus	Pou2f2	ENSRNOG00000055650
drosophila_melanogaster	acj6	FBGN0000028
drosophila_melanogaster	vvl	FBGN0086680
caenorhabditis_elegans		WBGENE00000441
caenorhabditis_elegans		WBGENE00006818

Paralogs (17): POU1F1 (ENSG00000064835), POU4F3 (ENSG00000091010), POU6F2 (ENSG00000106536), POU2F3 (ENSG00000137709), POU2F1 (ENSG00000143190), POU4F2 (ENSG00000151615), POU4F1 (ENSG00000152192), HDX (ENSG00000165259), POU6F1 (ENSG00000184271), POU3F2 (ENSG00000184486), POU3F1 (ENSG00000185668), POU3F4 (ENSG00000196767), POU3F3 (ENSG00000198914), CCDC160 (ENSG00000203952), POU5F1 (ENSG00000204531), POU5F1B (ENSG00000212993), POU5F2 (ENSG00000248483)

Protein

Protein identifiers

POU domain, class 2, transcription factor 2 — P09086 (reviewed: P09086)

Alternative names: Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2, Octamer-binding protein 2, Octamer-binding transcription factor 2

All UniProt accessions (15): A0A0D9SF23, A0A1B0GUT9, A0A1B0GV81, A0A1B0GW97, A0A8I5KYI8, B5ME60, P09086, E9PR37, H0YKT2, H0YLL6, H0YNG1, H0YNW1, M0R1I6, U3KQ96, U3KQN1

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that specifically binds to the octamer motif (5’-ATTTGCAT-3’). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Activates the U2 small nuclear RNA (snRNA) promoter.

Subunit / interactions. Interacts with NR3C1, AR and PGR. Interacts with POU2AF1; the interaction increases POU2F2 transactivation activity.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Isoform 3 is B-cell specific. Isoform 5 is expressed in B-cells and the immunoglobulin-expressing T-cell line MOLT-4, but not in the T-cell line BW5147.

Activity regulation. Transactivation activity is enhanced by transcriptional coactivator POU2AF1.

Miscellaneous. Incomplete sequence.

Similarity. Belongs to the POU transcription factor family. Class-2 subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
P09086-1	1	yes
P09086-2	2
P09086-3	3
P09086-4	4
P09086-5	5, Oct-2B

RefSeq proteins (10): NP_001193954, NP_001193955, NP_001234923, NP_001380863, NP_001380864, NP_001380865, NP_001381305, NP_001381306, NP_001381307, NP_002689 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000327	POU_dom	Domain
IPR000972	TF_octamer	Family
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR010982	Lambda_DNA-bd_dom_sf	Homologous_superfamily
IPR013847	POU	Domain
IPR017970	Homeobox_CS	Conserved_site
IPR050255	POU_domain_TF	Family

Pfam: PF00046, PF00157

UniProt features (28 total): helix 7, region of interest 6, compositionally biased region 5, splice variant 5, chain 1, domain 1, mutagenesis site 1, DNA-binding region 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9DZM	X-RAY DIFFRACTION	2.54
1HDP	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P09086-F1	60.37	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
340–342	suppresses dna-binding ability.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)

MSigDB gene sets: 296 (showing top): PID_BCR_5PATHWAY, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_CELLULAR_RESPONSE_TO_VIRUS, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_CYTOKINE_PRODUCTION, GOBP_HUMORAL_IMMUNE_RESPONSE, BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN, MODULE_38, XU_GH1_EXOGENOUS_TARGETS_UP, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_6_PRODUCTION, SCHLOSSER_SERUM_RESPONSE_UP, MODULE_112, SHEN_SMARCA2_TARGETS_DN, GOBP_RESPONSE_TO_VIRUS

GO Biological Process (11): regulation of transcription by RNA polymerase II (GO:0006357), humoral immune response (GO:0006959), positive regulation of interleukin-6 production (GO:0032755), positive regulation of transcription by RNA polymerase II (GO:0045944), cellular response to virus (GO:0098586), mature B cell differentiation (GO:0002335), regulation of DNA-templated transcription (GO:0006355), spermidine transport (GO:0015848), positive regulation of DNA-templated transcription (GO:0045893), cell maturation (GO:0048469), spermidine transmembrane transport (GO:1903711)

GO Molecular Function (11): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), sequence-specific DNA binding (GO:0043565), sequence-specific double-stranded DNA binding (GO:1990837), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), protein binding (GO:0005515), spermidine transmembrane transporter activity (GO:0015606), protein domain specific binding (GO:0019904)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Differentiation of T cells	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
DNA-templated transcription	2
immune response	1
positive regulation of cytokine production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
positive regulation of DNA-templated transcription	1
response to virus	1
B cell differentiation	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
polyamine transport	1
positive regulation of RNA biosynthetic process	1
cell development	1
cellular developmental process	1
anatomical structure maturation	1
spermidine transport	1
polyamine transmembrane transport	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
DNA binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
binding	1
polyamine transmembrane transporter activity	1
spermidine transmembrane transport	1
protein binding	1

Protein interactions and networks

STRING

1420 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
POU2F2	POU2AF1	Q16633	803
POU2F2	HCFC2	Q9Y5Z7	764
POU2F2	CREB3	O43889	596
POU2F2	BCL11A	Q9H165	576
POU2F2	RUNX3	Q13761	572
POU2F2	HCFC1	P51610	544
POU2F2	NFKB1	P19838	522
POU2F2	SPRR2A	P35326	491
POU2F2	PAX5	Q02548	489
POU2F2	MSLN	Q13421	478
POU2F2	MYT1L	Q9UL68	467
POU2F2	NAMPT	P43490	461
POU2F2	EBF1	Q9UH73	458
POU2F2	ELF3	P78545	447
POU2F2	IRF4	Q15306	424

IntAct

22 interactions, top by confidence:

A	B	Type	Score
TMEM108	TCAF2	psi-mi:“MI:0914”(association)	0.530
POU2F2	CYRIB	psi-mi:“MI:0915”(physical association)	0.400
POU2F2	E6	psi-mi:“MI:0915”(physical association)	0.370
IFNA10	POU2F2	psi-mi:“MI:0915”(physical association)	0.370
IFNA21	POU2F2	psi-mi:“MI:0915”(physical association)	0.370
IFNA4	POU2F2	psi-mi:“MI:0915”(physical association)	0.370
IL25	POU2F2	psi-mi:“MI:0915”(physical association)	0.370
POU2AF1	POU2F2	psi-mi:“MI:0915”(physical association)	0.370
FOXC2	ZNF536	psi-mi:“MI:0914”(association)	0.350
FOXJ2	TCERG1	psi-mi:“MI:0914”(association)	0.350
FOXS1	DDX39A	psi-mi:“MI:0914”(association)	0.350
TEAD2	DDX39A	psi-mi:“MI:0914”(association)	0.350
AQP3	RTL8C	psi-mi:“MI:0914”(association)	0.350
POU2F2	SMARCA4	psi-mi:“MI:2364”(proximity)	0.270
SMARCA4	POU2F2	psi-mi:“MI:2364”(proximity)	0.270
POU2F2	BRAF	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (37): POU2F2 (Affinity Capture-MS), POU2F2 (Affinity Capture-MS), POU2F2 (Affinity Capture-MS), POU2F2 (Affinity Capture-MS), POU2F2 (Affinity Capture-MS), GAPDH (Reconstituted Complex), POU2F2 (Reconstituted Complex), MSX2 (Two-hybrid), ESR1 (Reconstituted Complex), NR3C1 (Reconstituted Complex), AR (Reconstituted Complex), PGR (Reconstituted Complex), POU2F2 (Reconstituted Complex), MNAT1 (Reconstituted Complex), POU2F2 (Reconstituted Complex)

ESM2 similar proteins: A0A1L8FFY5, A1L0Z1, A1L1N5, B3DM25, B7ZQA9, D3ZTL1, P09086, P10037, P20268, P20912, P23760, P23899, P24350, P24610, P27889, P31362, P31363, P31364, P31365, P35680, P42571, P47239, P49335, P56224, P62515, P62516, P70030, P79745, P79746, Q00196, Q03365, Q05041, Q08478, Q15319, Q29013, Q4QQQ7, Q561L5, Q5RER5, Q63955, Q6DJN3

Diamond homologs: A0A1L8FFY5, A1L0Z1, A7Y7W2, B3DM23, B3DM25, B7ZQA9, D3ZTL1, G3V7L5, O97552, P09086, P10036, P10037, P13528, P14859, P15143, P16143, P16241, P17208, P20263, P20264, P20265, P20266, P20267, P20268, P20912, P20913, P20914, P21952, P24350, P25425, P28069, P31360, P31361, P31362, P31363, P31364, P31365, P31367, P31368, P31369

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
YES1	“up-regulates activity”	POU2F2	phosphorylation
POU2AF1	up-regulates	POU2F2	binding
HMGB2	“up-regulates activity”	POU2F2	binding

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 3 cancer types — DLBCLNOS, MLYM, NHL.

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2233 predictions. Top by Δscore:

Variant	Effect	Δscore
19:42091939:TT:T	acceptor_gain	1.0000
19:42091941:C:CC	acceptor_gain	1.0000
19:42093893:GACC:G	acceptor_loss	1.0000
19:42093896:C:CA	acceptor_loss	1.0000
19:42093896:C:CC	acceptor_gain	1.0000
19:42093897:T:A	acceptor_loss	1.0000
19:42095301:G:C	donor_gain	1.0000
19:42095312:T:TA	donor_gain	1.0000
19:42095313:C:A	donor_gain	1.0000
19:42095340:A:AC	donor_gain	1.0000
19:42095341:C:CC	donor_gain	1.0000
19:42095401:T:TA	donor_gain	1.0000
19:42095458:TGGTT:T	acceptor_gain	1.0000
19:42095460:GTT:G	acceptor_gain	1.0000
19:42095461:TT:T	acceptor_gain	1.0000
19:42095461:TTCTG:T	acceptor_loss	1.0000
19:42095463:C:CC	acceptor_gain	1.0000
19:42095539:CCTCA:C	donor_loss	1.0000
19:42095541:TCA:T	donor_loss	1.0000
19:42095542:CA:C	donor_loss	1.0000
19:42095543:A:AC	donor_gain	1.0000
19:42095543:ACCGC:A	donor_loss	1.0000
19:42095544:C:CG	donor_gain	1.0000
19:42095544:CCG:C	donor_gain	1.0000
19:42095690:GTCT:G	acceptor_gain	1.0000
19:42095692:CT:C	acceptor_gain	1.0000
19:42095694:C:CC	acceptor_gain	1.0000
19:42095699:C:CT	acceptor_gain	1.0000
19:42095702:C:CT	acceptor_gain	1.0000
19:42095702:C:T	acceptor_gain	1.0000

AlphaMissense

4013 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:42095357:G:A	R354C	1.000
19:42095357:G:T	R354S	1.000
19:42095358:T:A	K353N	1.000
19:42095358:T:G	K353N	1.000
19:42095359:T:A	K353I	1.000
19:42095360:T:C	K353E	1.000
19:42095364:C:A	K351N	1.000
19:42095364:C:G	K351N	1.000
19:42095365:T:A	K351M	1.000
19:42095366:T:C	K351E	1.000
19:42095366:T:G	K351Q	1.000
19:42095367:C:A	Q350H	1.000
19:42095367:C:G	Q350H	1.000
19:42095368:T:C	Q350R	1.000
19:42095368:T:G	Q350P	1.000
19:42095369:G:T	Q350K	1.000
19:42095371:C:G	R349P	1.000
19:42095371:C:T	R349H	1.000
19:42095372:G:A	R349C	1.000
19:42095372:G:C	R349G	1.000
19:42095372:G:T	R349S	1.000
19:42095374:C:G	R348P	1.000
19:42095375:G:A	R348W	1.000
19:42095375:G:C	R348G	1.000
19:42095376:G:C	N347K	1.000
19:42095376:G:T	N347K	1.000
19:42095377:T:A	N347I	1.000
19:42095377:T:G	N347T	1.000
19:42095378:T:A	N347Y	1.000
19:42095378:T:C	N347D	1.000

dbSNP variants (sampled 300 via entrez): RS1000035858 (19:42121133 T>C), RS1000114525 (19:42175062 G>A), RS1000128321 (19:42116643 C>G), RS1000153127 (19:42110609 T>A), RS1000181565 (19:42192543 G>A), RS1000185771 (19:42131212 G>T), RS1000198845 (19:42149773 A>G), RS1000235501 (19:42095876 C>G,T), RS1000254055 (19:42155174 C>G,T), RS1000289252 (19:42135777 G>A,T), RS1000312215 (19:42197148 G>C), RS1000312748 (19:42154943 A>G,T), RS1000339515 (19:42109994 C>T), RS1000340952 (19:42137959 G>A), RS1000342559 (19:42088415 G>A)

Disease associations

OMIM: gene MIM:164176 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST006083_7	Prostate cancer (advanced)	4.000000e-06
GCST006085_101	Prostate cancer	9.000000e-09
GCST007328_66	Alcohol consumption (drinks per week)	3.000000e-09
GCST007576_331	Chronotype	3.000000e-11
GCST010143_27	Meat-related diet	3.000000e-09
GCST90002381_344	Eosinophil count	2.000000e-10
GCST90002393_660	Monocyte count	2.000000e-13

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0008328	chronotype measurement
EFO:0008111	diet measurement
EFO:0004842	eosinophil count
EFO:0005091	monocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3509582 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 5,282 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL237500	LINAGLIPTIN	4	5,282

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

6 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs195854	POU2F2		0.00	0
rs195862	POU2F2, POU3F2		0.00	0
rs1869641	POU2F2		0.00	0
rs1883306	POU2F2		0.00	0
rs2444933	POU2F2		0.00	0
rs3823036	POU2F2, POU3F2		0.00	0

Binding affinities (BindingDB)

9 measured of 9 human assays (9 total across all organisms); most potent 9 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(2R,6S)-10-hydroxy-7-methyl-8,11-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-1,7-diazatricyclo[7.4.0.02,6]trideca-9,12-diene-12-carboxamide	IC50	216 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2S,6R)-10-hydroxy-7-methyl-8,11-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-1,7-diazatricyclo[7.4.0.02,6]trideca-9,12-diene-12-carboxamide	IC50	2490 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(4aR,11aS)-7-hydroxy-5-methyl-6,8-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-1,2,3,4,4a,11a-hexahydropyrido[1,2-a]quinoxaline-9-carboxamide	IC50	2510 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2R,7S)-8-ethyl-11-hydroxy-9,12-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-5-oxa-1,8-diazatricyclo[8.4.0.02,7]tetradeca-10,13-diene-13-carboxamide	IC50	6400 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2R,7R)-11-hydroxy-9,12-dioxo-8-(2,2,2-trifluoroethyl)-N-[(2,4,6-trifluorophenyl)methyl]-5-oxa-1,8-diazatricyclo[8.4.0.02,7]tetradeca-10,13-diene-13-carboxamide	IC50	10000 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2S,7S)-11-hydroxy-9,12-dioxo-8-(2,2,2-trifluoroethyl)-N-[(2,4,6-trifluorophenyl)methyl]-5-oxa-1,8-diazatricyclo[8.4.0.02,7]tetradeca-10,13-diene-13-carboxamide	IC50	10000 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2S,7S)-N-[(3-chloro-2,4-difluorophenyl)methyl]-8-ethyl-11-hydroxy-9,12-dioxo-5-oxa-1,8-diazatricyclo[8.4.0.02,7]tetradeca-10,13-diene-13-carboxamide	IC50	10000 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2S,6R)-N-[(3-chloro-2,4-difluorophenyl)methyl]-7-ethyl-10-hydroxy-8,11-dioxo-5-oxa-1,7-diazatricyclo[7.4.0.02,6]trideca-9,12-diene-12-carboxamide	IC50	10000 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
(2R,6S)-10-hydroxy-8,11-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-1,7-diazatricyclo[7.4.0.02,6]trideca-9,12-diene-12-carboxamide	IC50	10000 nM	US-9795602: Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

ChEMBL bioactivities

10 potent at pChembl≥5 of 11 total, top 10 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.67	IC50	216	nM	CHEMBL5971009
5.60	IC50	2493	nM	CHEMBL6007742
5.60	IC50	2511	nM	CHEMBL5843987
5.28	IC50	5300	nM	CHEMBL5563848
5.19	IC50	6400	nM	CHEMBL5920219
5.00	IC50	1e+04	nM	CHEMBL5892608
5.00	IC50	1e+04	nM	CHEMBL5834509
5.00	IC50	1e+04	nM	CHEMBL5820959
5.00	IC50	1e+04	nM	CHEMBL5934829
5.00	IC50	1e+04	nM	CHEMBL5995688

PubChem BioAssay actives

1 with measured affinity, of 46 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-6-[4-[[(3S,5R)-3-methyl-5-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)piperazin-1-yl]methyl]triazol-2-yl]pyridine-3-carbonitrile	2077522: Inhibition of OCT2 (unknown origin)	ic50	5.3000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Formaldehyde	decreases expression, increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, increases methylation	1
sotorasib	affects cotreatment, decreases expression	1
sodium arsenite	increases expression	1
pyrrolidine dithiocarbamic acid	affects cotreatment, decreases reaction, increases expression	1
(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide	decreases expression	1
oligofectamine	increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
trametinib	affects cotreatment, decreases expression	1
PCI 5002	increases expression, affects cotreatment	1
NVP-BKM120	decreases expression, affects cotreatment	1
Aripiprazole	affects cotreatment, increases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Vorinostat	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Cisplatin	decreases reaction, increases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Estradiol	increases expression, affects cotreatment	1
Ethyl Methanesulfonate	increases expression	1
Nickel	increases expression	1
Omeprazole	decreases reaction, increases expression	1
Ozone	affects cotreatment, increases expression	1
Silicon Dioxide	increases expression	1
Tetradecanoylphorbol Acetate	increases expression, affects cotreatment, decreases reaction	1

ChEMBL screening assays

24 unique, capped per target: 14 admet, 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3528440	ADMET	Drug transport in human OAT2 expressed in HEK Flp-In cells	Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. — Drug Metab Dispos
CHEMBL4678468	Binding	Inhibition of OCT2 (unknown origin) up to 50 uM	Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. — J Med Chem

Cellosaurus cell lines

6 cell lines: 3 embryonic stem cell, 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A5L6	SEES3-1V human POU2F2, clone1	Embryonic stem cell	Male
CVCL_A5L7	SEES3-1V human POU2F2, clone2	Embryonic stem cell	Male
CVCL_A5L8	SEES3-1V human POU2F2, clone3	Embryonic stem cell	Male
CVCL_B8MT	Abcam HCT 116 POU2F2 KO	Cancer cell line	Male
CVCL_B9Q2	Abcam A-549 POU2F2 KO	Cancer cell line	Male
CVCL_D2GZ	Abcam MCF-7 POU2F2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.